The Competition Commission of India cleared BNP Paribas Cardif to buy a 26% stake in IndiaFirst Life Insurance this week, removing the last regulatory hurdle on a deal first announced in July. The seller is Warburg Pincus, the private equity firm that has held the stake since early 2019. The price implies the company is worth roughly $1.35 billion — about 3.5 times what Warburg paid for the same 26% seven years ago.
That alone would be a clean private-equity-exit story. What makes it a stranger one is who's buying. BNP Paribas Cardif was SBI Life Insurance's foreign co-promoter from that company's founding, and between March 2019 and March 2021 it sold almost the entire position — a 9% block to Carlyle Group, another 5%, then 2.5%, then a final 5% in March 2021 that took its residual holding down to 0.2%. Across those four years, the insurer that is now paying up for a 26% slice of one Indian bank-led life insurer was simultaneously dismantling a near-identical position in India's largest one.
Two bancassurance bets, two different trades
IndiaFirst Life was built on the same model SBI Life was: an Indian public-sector bank supplies the branch network and the customer base, a foreign insurer supplies underwriting expertise and capital, and the bank's distribution does most of the selling. IndiaFirst launched in 2010 with Bank of Baroda, the since-merged Andhra Bank, and UK insurer Legal & General as its three promoters. Legal & General exited in 2018 as part of a wider retreat from markets outside its core UK and US business, selling its 26% to Warburg Pincus — structured through the PE firm's India vehicle, Carmel Point Investments India — for ₹710.5 crore.
| SBI Life (2019-21 trade) | IndiaFirst Life (2026 trade) | |
|---|---|---|
| BNP Paribas Cardif's role | Seller, down to 0.2% | Buyer, up to 26% |
| Bank partner | State Bank of India | Bank of Baroda |
| Counterparty | Carlyle Group, open market | Warburg Pincus (PE exit) |
| What triggered the stake | Post-IPO promoter dilution | Regulatory reform + PE exit window |
The SBI Life sales were not really a verdict on India — they tracked SBI Life's 2017 listing and the promoter-dilution norms that come with it, and Carlyle was the buyer stepping into the gap BNP Paribas Cardif's selling created. It's a different kind of transaction to read against the IndiaFirst purchase, not a simple "left, came back" story. But the fact remains that the same insurer had a seat at India's biggest bank-led insurer and chose to shrink it to almost nothing, then turned around and paid a premium to build a large stake in a smaller rival.
What changed between the two trades
The gap between those two decisions is a law that didn't exist when BNP Paribas Cardif was selling SBI Life stock. India's 2025 Union Budget raised the FDI cap on insurance from 74% to 100%, and the enabling legislation — the Sabka Bima Sabki Raksha Act — was formally notified on December 12, 2025, seven months before BNP Paribas Cardif signed its IndiaFirst agreement. Under the old 74% ceiling, a foreign insurer buying into an Indian bancassurance JV was always going to be a minority partner relative to the bank; 100% FDI means a strategic buyer can now, in principle, build a controlling position if the economics justify it.
BNP Paribas Cardif isn't doing that here — 26% leaves Bank of Baroda comfortably in control at 65%, with Union Bank of India (which inherited a stake through Corporation Bank's 2020 merger into it) holding the remaining 9%. That's worth sitting with: the reform that was supposed to unlock full foreign ownership produced a deal where the foreign insurer bought the exact same 26% the departing private equity firm held, not more. The read that fits the facts is narrower than "foreign capital floods in post-liberalisation." It's that a reform removing a ceiling makes deals easier to clear regulatory review, not that it automatically pushes buyers toward the new ceiling. A strategic insurer buying into a bank's distribution network has every reason to leave the bank in charge — the bank's branches are the product.
The numbers behind the exit
Warburg Pincus's arithmetic is the more straightforward part of this. ₹710.5 crore for 26% in early 2019 implied a company valuation of roughly ₹2,733 crore — call it $390 million at the exchange rate of the time. The implied valuation in the BNP Paribas Cardif deal is reported at close to $350 million for the 26% stake alone, which puts full-company value at roughly $1.35 billion. In dollar terms that's about a 3.5x gain in seven years; in rupee terms, with the currency having moved from roughly ₹70 to the dollar in 2019 to around ₹95 now, the multiple on a rupee basis is meaningfully higher still.
That return has a second data point sitting right next to it. In the same week CCI cleared the IndiaFirst deal, Jio Financial Services and Allianz Europe each injected ₹320.05 crore — ₹640.10 crore total — into Jio Allianz General Insurance, their 50:50 general-insurance joint venture, via a rights issue to fund expansion. Allianz re-entered India in 2025 after decades running its life and general insurance JVs with Bajaj Finserv, a partnership it also unwound as part of its own India repositioning. Two different foreign insurers, in the same week, making fresh India commitments after each had spent the recent past selling down or walking away from an earlier Indian partnership. If that's a pattern rather than a coincidence, it says foreign insurers are treating 2025-26 as a genuine reset point for how they want to be positioned in India — not simply adding to what they already had, but choosing new partners under a new law.
What to verify: the exact closing date of the BNP Paribas Cardif-Warburg Pincus transaction wasn't available at the time of writing — CCI clearance removes the regulatory condition but doesn't itself close the deal. IRDAI sign-off, typically the final step in transactions like this, should be watched for in the coming weeks.
